What it's for (Indications)
- Ephedrine, marketed under various names including the example 'Vepressor', is primarily indicated for the treatment of clinically significant hypotension occurring in the setting of spinal or epidural anesthesia.
- Its primary role in this context is to increase blood pressure by inducing peripheral vasoconstriction and enhancing cardiac output, thereby counteracting the vasodilatory effects of regional anesthesia.
- While historically utilized as a bronchodilator, nasal decongestant, and central nervous system stimulant, these applications are largely superseded by more selective and safer pharmacological agents.
- The current clinical focus for ephedrine injection is its pressor effect in acute hypotensive states.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Ephedrine sulfate is typically administered intravenously. The dosage must be carefully individualized based on the patient's hemodynamic response, age, weight, and existing comorbidities. For the treatment of hypotension during spinal or epidural anesthesia, an initial intravenous bolus of 5 to 10 mg is commonly administered. This dose may be repeated, if necessary, every 3 to 4 minutes, not exceeding a total cumulative dose of 50 mg in any 24-hour period, or as guided by clinical response and the patient's cardiovascular status. The lowest effective dose should always be used to achieve the desired pressor effect, and continuous hemodynamic monitoring is essential during administration to promptly detect and manage any adverse effects or over-response. |
Safety & Warnings
Common Side Effects
- Common side effects associated with ephedrine administration include, but are not limited to, tachycardia, palpitations, hypertension, anxiety, restlessness, tremor, headache, dizziness, insomnia, and nausea or vomiting.
- More serious and potentially life-threatening adverse reactions can occur, especially with higher doses or in susceptible individuals.
- These severe effects may include ventricular arrhythmias (e.
- g.
- , ventricular fibrillation), myocardial infarction, angina pectoris, stroke, cerebral hemorrhage, pulmonary edema, and hypertensive crisis.
- Patients may also experience urinary retention, particularly those with prostatic hypertrophy.
- Any signs of severe cardiovascular or central nervous system adverse effects warrant immediate medical attention and potential cessation of the drug.
Serious Warnings
- Black Box Warning: Serious Warnings: Ephedrine carries significant and potentially life-threatening risks, predominantly cardiovascular and cerebrovascular in nature. These severe adverse events, including myocardial infarction, cerebral hemorrhage, stroke, and profound cardiac arrhythmias (such as ventricular fibrillation), can occur, particularly with excessive dosage, rapid administration, or in individuals with pre-existing cardiovascular vulnerabilities. A critical warning emphasizes the substantial risk of severe hypertensive crisis, especially when ephedrine is co-administered with monoamine oxidase inhibitors (MAOIs) or in patients with poorly controlled or severe hypertension. Prescribers and patients must also be aware of the inherent central nervous system stimulant properties of ephedrine, which have historically been associated with a potential for abuse and the development of psychological dependence. Due to the potency of its pharmacological effects, meticulous patient selection, precise dosage titration to the lowest effective dose, and continuous, rigorous hemodynamic monitoring are absolutely imperative throughout the treatment period to minimize these serious risks and ensure the utmost patient safety.
- Ephedrine should be used with extreme caution in patients with pre-existing cardiovascular conditions such as hypertension, ischemic heart disease, angina pectoris, or cardiac arrhythmias, as it can exacerbate these conditions.
- Caution is also advised in patients with hyperthyroidism, diabetes mellitus, prostatic hypertrophy, narrow-angle glaucoma, and renal impairment.
- Repeated administration of ephedrine may lead to tachyphylaxis, resulting in a diminished pressor response.
- Concomitant use with certain medications, including monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or oxytocics, can lead to severe hypertensive reactions.
- The potential for central nervous system stimulation requires careful monitoring, and the drug should not be used in individuals with a history of substance abuse due to its stimulant properties and potential for psychological dependence.
How it Works (Mechanism of Action)
Ephedrine exerts its pharmacological effects through a dual mechanism, acting both directly and indirectly on adrenergic receptors. It directly stimulates alpha-1, beta-1, and beta-2 adrenergic receptors, leading to vasoconstriction (via alpha-1), increased heart rate and myocardial contractility (via beta-1), and bronchodilation (via beta-2). Additionally, ephedrine indirectly promotes the release of endogenous norepinephrine from sympathetic nerve endings, thereby amplifying its sympathomimetic effects. This combined direct and indirect action results in a significant increase in systemic blood pressure, an elevation in heart rate, and an increase in cardiac output, which are crucial for its use in treating hypotension. Its action is less potent and more prolonged than that of epinephrine.